Sangtian Liu

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Yijun Jia, Xuefei Li, Tao Jiang et al. · International Journal of Cancer · 2019 · 162 citations · Full text

Medicine, Immunology, Oncology +17

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

Sangtian Liu, Fengying Wu, Xuefei Li et al. · Frontiers in Oncology · 2021 · 34 citations · Full text

Medicine, Immunology, Oncology +17

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

Yayi He, Sangtian Liu, Paul A. Bunn et al. · Drug Design Development and Therapy · 2018 · 31 citations · Full text

Life Sciences, Immunology, Oncology +17

Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice

Yijun Jia, Sha Zhao, Tao Jiang et al. · Lung Cancer · 2019 · 26 citations

Medicine, Cancer Biology, Oncology +16

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

Ruoshuang Han, Yijun Jia, Xuefei Li et al. · Translational Lung Cancer Research · 2021 · 26 citations · Full text

Medicine, Oncology, Pharmacotherapy +17